FDA drafts plan for easier interchangeable biosimilar drugs
Published Date: 9/18/2026
Notice
Summary
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Draft Strategy to Support Biosimilars
The FDA published a draft Strategy Document that summarizes the September 19, 2025 public workshop and describes FDA's future directions to support development of interchangeable biosimilar products under the BsUFA III commitments for fiscal years 2023 through 2027. The Agency is accepting public comments on the draft through November 17, 2026.
Education for Patients and Providers
FDA says it will provide educational resources for healthcare providers and patients about interchangeable biosimilar products to help build confidence in their safety and effectiveness. The draft Strategy Document summarizes this planned focus and is open for public comment through November 17, 2026.
Focus on Science and Human Factors
The draft Strategy Document says FDA will continue to follow evolving science and address scientific topics such as analytical data considerations and user interface and human factors when supporting interchangeable biosimilar development. These areas were discussed at the September 19, 2025 workshop and are summarized in the draft available for comment until November 17, 2026.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-19165, Certain Gyro-Stabilized Electric Unicycles and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Granting Complainants' Unopposed Motion To Amend the Complaint and Notice of Investigation
The U.S. International Trade Commission is moving forward with a case about gyro-stabilized electric unicycles, adding a new company, LeaperKim Coyote, to the investigation. This affects companies importing or selling these unicycles in the U.S., with potential impacts on sales and patents. The case started in March 2026 and is now expanding, signaling serious attention to patent rights and market control.
Next: 2026-19167, U.S. Strategic Command Strategic Advisory Group; Notice of Federal Advisory Committee Closed Meeting; Republication
The U.S. Strategic Command Strategic Advisory Group will hold a secret meeting on September 21-22, 2026, to discuss important military and technology topics like nuclear stockpiles and new threats. This meeting affects military leaders and advisors but won’t cost extra money or change public rules. The notice was reissued because they missed a public announcement deadline but got a special waiver to proceed anyway.